Report cover image

Global Attenuated Vaccine for Human Rabies Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 193 Pages
SKU # APRC20355403

Description

Summary

According to APO Research, The global Attenuated Vaccine for Human Rabies market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Attenuated Vaccine for Human Rabies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Attenuated Vaccine for Human Rabies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Attenuated Vaccine for Human Rabies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Attenuated Vaccine for Human Rabies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Attenuated Vaccine for Human Rabies include Changchun Zhuoyi Biological Co., Ltd, Wuhan Institute of Biological Products Co., Ltd, Shandong Yidu Biotechnology Co., Ltd, Ningbo Rongan Biopharmaceutical Co., Ltd, Liaoning Yisheng Biopharmaceutical Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Guangzhou Nuocheng Biological Products Co., Ltd, Chengdu Kanghua Biological Products Co., Ltd and AstraZeneca, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Attenuated Vaccine for Human Rabies, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Attenuated Vaccine for Human Rabies, also provides the sales of main regions and countries. Of the upcoming market potential for Attenuated Vaccine for Human Rabies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Attenuated Vaccine for Human Rabies sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Attenuated Vaccine for Human Rabies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Attenuated Vaccine for Human Rabies sales, projected growth trends, production technology, application and end-user industry.

Attenuated Vaccine for Human Rabies Segment by Company

Changchun Zhuoyi Biological Co., Ltd
Wuhan Institute of Biological Products Co., Ltd
Shandong Yidu Biotechnology Co., Ltd
Ningbo Rongan Biopharmaceutical Co., Ltd
Liaoning Yisheng Biopharmaceutical Co., Ltd
Lanzhou Institute of Biological Products Co., Ltd
Guangzhou Nuocheng Biological Products Co., Ltd
Chengdu Kanghua Biological Products Co., Ltd
AstraZeneca
Sanofi Pasteur, Inc
Pfizer Inc
Novartis AG
Merck & Co Inc
GlaxoSmithKline
Cadila Pharmaceuticals Ltd
Attenuated Vaccine for Human Rabies Segment by Type

Vero Cell
Human Diploid Cell
Attenuated Vaccine for Human Rabies Segment by Application

Hospital
Clinic
Attenuated Vaccine for Human Rabies Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine for Human Rabies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine for Human Rabies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine for Human Rabies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Attenuated Vaccine for Human Rabies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Attenuated Vaccine for Human Rabies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Attenuated Vaccine for Human Rabies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Attenuated Vaccine for Human Rabies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Attenuated Vaccine for Human Rabies Market Size, 2020 VS 2024 VS 2031
1.3 Global Attenuated Vaccine for Human Rabies Market Size Estimates and Forecasts (2020-2031)
1.4 Global Attenuated Vaccine for Human Rabies Sales Estimates and Forecasts (2020-2031)
1.5 Global Attenuated Vaccine for Human Rabies Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Attenuated Vaccine for Human Rabies Market Dynamics
2.1 Attenuated Vaccine for Human Rabies Industry Trends
2.2 Attenuated Vaccine for Human Rabies Industry Drivers
2.3 Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges
2.4 Attenuated Vaccine for Human Rabies Industry Restraints
3 Attenuated Vaccine for Human Rabies Market by Manufacturers
3.1 Global Attenuated Vaccine for Human Rabies Revenue by Manufacturers (2020-2025)
3.2 Global Attenuated Vaccine for Human Rabies Sales by Manufacturers (2020-2025)
3.3 Global Attenuated Vaccine for Human Rabies Average Sales Price by Manufacturers (2020-2025)
3.4 Global Attenuated Vaccine for Human Rabies Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Attenuated Vaccine for Human Rabies Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Attenuated Vaccine for Human Rabies Manufacturers, Product Type & Application
3.7 Global Attenuated Vaccine for Human Rabies Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Attenuated Vaccine for Human Rabies Market CR5 and HHI
3.8.2 Global Top 5 and 10 Attenuated Vaccine for Human Rabies Players Market Share by Revenue in 2024
3.8.3 2024 Attenuated Vaccine for Human Rabies Tier 1, Tier 2, and Tier 3
4 Attenuated Vaccine for Human Rabies Market by Type
4.1 Attenuated Vaccine for Human Rabies Type Introduction
4.1.1 Vero Cell
4.1.2 Human Diploid Cell
4.2 Global Attenuated Vaccine for Human Rabies Sales by Type
4.2.1 Global Attenuated Vaccine for Human Rabies Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Attenuated Vaccine for Human Rabies Sales by Type (2020-2031)
4.2.3 Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2020-2031)
4.3 Global Attenuated Vaccine for Human Rabies Revenue by Type
4.3.1 Global Attenuated Vaccine for Human Rabies Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Attenuated Vaccine for Human Rabies Revenue by Type (2020-2031)
4.3.3 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2020-2031)
5 Attenuated Vaccine for Human Rabies Market by Application
5.1 Attenuated Vaccine for Human Rabies Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.2 Global Attenuated Vaccine for Human Rabies Sales by Application
5.2.1 Global Attenuated Vaccine for Human Rabies Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Attenuated Vaccine for Human Rabies Sales by Application (2020-2031)
5.2.3 Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2020-2031)
5.3 Global Attenuated Vaccine for Human Rabies Revenue by Application
5.3.1 Global Attenuated Vaccine for Human Rabies Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Attenuated Vaccine for Human Rabies Revenue by Application (2020-2031)
5.3.3 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2020-2031)
6 Global Attenuated Vaccine for Human Rabies Sales by Region
6.1 Global Attenuated Vaccine for Human Rabies Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Attenuated Vaccine for Human Rabies Sales by Region (2020-2031)
6.2.1 Global Attenuated Vaccine for Human Rabies Sales by Region (2020-2025)
6.2.2 Global Attenuated Vaccine for Human Rabies Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Attenuated Vaccine for Human Rabies Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Attenuated Vaccine for Human Rabies Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Attenuated Vaccine for Human Rabies Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Attenuated Vaccine for Human Rabies Revenue by Region
7.1 Global Attenuated Vaccine for Human Rabies Revenue by Region
7.1.1 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Attenuated Vaccine for Human Rabies Revenue by Region (2020-2025)
7.1.3 Global Attenuated Vaccine for Human Rabies Revenue by Region (2026-2031)
7.1.4 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Attenuated Vaccine for Human Rabies Revenue (2020-2031)
7.2.2 North America Attenuated Vaccine for Human Rabies Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Attenuated Vaccine for Human Rabies Revenue (2020-2031)
7.3.2 Europe Attenuated Vaccine for Human Rabies Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Attenuated Vaccine for Human Rabies Revenue (2020-2031)
7.4.2 Asia-Pacific Attenuated Vaccine for Human Rabies Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Attenuated Vaccine for Human Rabies Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Attenuated Vaccine for Human Rabies Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Changchun Zhuoyi Biological Co., Ltd
8.1.1 Changchun Zhuoyi Biological Co., Ltd Comapny Information
8.1.2 Changchun Zhuoyi Biological Co., Ltd Business Overview
8.1.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
8.1.5 Changchun Zhuoyi Biological Co., Ltd Recent Developments
8.2 Wuhan Institute of Biological Products Co., Ltd
8.2.1 Wuhan Institute of Biological Products Co., Ltd Comapny Information
8.2.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
8.2.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
8.2.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
8.3 Shandong Yidu Biotechnology Co., Ltd
8.3.1 Shandong Yidu Biotechnology Co., Ltd Comapny Information
8.3.2 Shandong Yidu Biotechnology Co., Ltd Business Overview
8.3.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
8.3.5 Shandong Yidu Biotechnology Co., Ltd Recent Developments
8.4 Ningbo Rongan Biopharmaceutical Co., Ltd
8.4.1 Ningbo Rongan Biopharmaceutical Co., Ltd Comapny Information
8.4.2 Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview
8.4.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
8.4.5 Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments
8.5 Liaoning Yisheng Biopharmaceutical Co., Ltd
8.5.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Comapny Information
8.5.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview
8.5.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
8.5.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments
8.6 Lanzhou Institute of Biological Products Co., Ltd
8.6.1 Lanzhou Institute of Biological Products Co., Ltd Comapny Information
8.6.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
8.6.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
8.6.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
8.7 Guangzhou Nuocheng Biological Products Co., Ltd
8.7.1 Guangzhou Nuocheng Biological Products Co., Ltd Comapny Information
8.7.2 Guangzhou Nuocheng Biological Products Co., Ltd Business Overview
8.7.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
8.7.5 Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments
8.8 Chengdu Kanghua Biological Products Co., Ltd
8.8.1 Chengdu Kanghua Biological Products Co., Ltd Comapny Information
8.8.2 Chengdu Kanghua Biological Products Co., Ltd Business Overview
8.8.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
8.8.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments
8.9 AstraZeneca
8.9.1 AstraZeneca Comapny Information
8.9.2 AstraZeneca Business Overview
8.9.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio
8.9.5 AstraZeneca Recent Developments
8.10 Sanofi Pasteur, Inc
8.10.1 Sanofi Pasteur, Inc Comapny Information
8.10.2 Sanofi Pasteur, Inc Business Overview
8.10.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio
8.10.5 Sanofi Pasteur, Inc Recent Developments
8.11 Pfizer Inc
8.11.1 Pfizer Inc Comapny Information
8.11.2 Pfizer Inc Business Overview
8.11.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio
8.11.5 Pfizer Inc Recent Developments
8.12 Novartis AG
8.12.1 Novartis AG Comapny Information
8.12.2 Novartis AG Business Overview
8.12.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio
8.12.5 Novartis AG Recent Developments
8.13 Merck & Co Inc
8.13.1 Merck & Co Inc Comapny Information
8.13.2 Merck & Co Inc Business Overview
8.13.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio
8.13.5 Merck & Co Inc Recent Developments
8.14 GlaxoSmithKline
8.14.1 GlaxoSmithKline Comapny Information
8.14.2 GlaxoSmithKline Business Overview
8.14.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio
8.14.5 GlaxoSmithKline Recent Developments
8.15 Cadila Pharmaceuticals Ltd
8.15.1 Cadila Pharmaceuticals Ltd Comapny Information
8.15.2 Cadila Pharmaceuticals Ltd Business Overview
8.15.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio
8.15.5 Cadila Pharmaceuticals Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Attenuated Vaccine for Human Rabies Value Chain Analysis
9.1.1 Attenuated Vaccine for Human Rabies Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Attenuated Vaccine for Human Rabies Production Mode & Process
9.2 Attenuated Vaccine for Human Rabies Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Attenuated Vaccine for Human Rabies Distributors
9.2.3 Attenuated Vaccine for Human Rabies Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.